Hodgkin's Patient and Medarex Reach Agreement

I wrote 2 blogs ago about Amanda, who has late stage Hodgkin's which has been resistant to conventional treatment. I received an e-mail today:



The past few days and weeks have been very difficult and challenging for the Twellman and Dieppa families and for Medarex. Mr. Drakeman, the President and CEO of Medarex, and the family worked closely together on some very complex and emotional issues. We are pleased to announce that a resolution has been reached, which meets the needs of the family and the goals of Medarex.



We wish to thank everyone for the overwhelming support and prayers for Amanda. We also wish to extend our gratitude to Medarex, Mr. Drakeman, and so many others that were instrumental in helping to bring this situation to a successful conclusion. More importantly, we give thanks to God.



Please keep Amanda in your prayers as she continues her battle with cancer.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap